- Home
- EDSA vs VRAX Comparison
EDSA vs VRAX Comparison
Compare EDSA & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- VRAX
- Stock Information
- Founded
- EDSA 2015
- VRAX 2013
- Country
- EDSA Canada
- VRAX United Kingdom
- Employees
- EDSA N/A
- VRAX N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EDSA Health Care
- VRAX Health Care
- Exchange
- EDSA Nasdaq
- VRAX Nasdaq
- Market Cap
- EDSA 6.2M
- VRAX 5.9M
- IPO Year
- EDSA N/A
- VRAX 2022
- Fundamental
- Price
- EDSA $2.26
- VRAX $0.99
- Analyst Decision
- EDSA Strong Buy
- VRAX Strong Buy
- Analyst Count
- EDSA 1
- VRAX 1
- Target Price
- EDSA $21.00
- VRAX $3.00
- AVG Volume (30 Days)
- EDSA 11.4K
- VRAX 298.2K
- Earning Date
- EDSA 05-09-2025
- VRAX 02-05-2025
- Dividend Yield
- EDSA N/A
- VRAX N/A
- EPS Growth
- EDSA N/A
- VRAX N/A
- EPS
- EDSA N/A
- VRAX N/A
- Revenue
- EDSA N/A
- VRAX $84,872.00
- Revenue This Year
- EDSA N/A
- VRAX $5,169.18
- Revenue Next Year
- EDSA N/A
- VRAX $66.97
- P/E Ratio
- EDSA N/A
- VRAX N/A
- Revenue Growth
- EDSA N/A
- VRAX 7.03
- 52 Week Low
- EDSA $1.55
- VRAX $0.60
- 52 Week High
- EDSA $5.59
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- EDSA 46.91
- VRAX 39.74
- Support Level
- EDSA $2.11
- VRAX $0.97
- Resistance Level
- EDSA $2.34
- VRAX $1.09
- Average True Range (ATR)
- EDSA 0.13
- VRAX 0.11
- MACD
- EDSA -0.01
- VRAX 0.02
- Stochastic Oscillator
- EDSA 40.45
- VRAX 33.37
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.